Jawed Fareed

Summary

Affiliation: Loyola University Medical Center
Country: USA

Publications

  1. ncbi request reprint Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques
    M Demir
    Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 7:38-43. 2001
  2. ncbi request reprint Development of generic low molecular weight heparins: a perspective
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 19:53-68, v-vi. 2005
  3. ncbi request reprint Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    J Fareed
    Hemostasis and Thrombosis Research Laboratoires, Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 27:176-92. 2008
  4. doi request reprint Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Jawed Fareed
    Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 14:385-92. 2008
  5. doi request reprint Metabolic differences of current thienopyridine antiplatelet agents
    Jawed Fareed
    Loyola University Chicago, Department of Pathology and Pharmacology, 2160 S First Avenue, Maywood, Illinois 60153, USA
    Expert Opin Drug Metab Toxicol 9:307-17. 2013
  6. ncbi request reprint Antithrombin and anti-Xa agents in the control of thrombogenesis
    J Fareed
    Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, IL, USA
    Pharmazie 56:S12-21. 2001
  7. doi request reprint A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population
    Jawed Fareed
    Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 17:164-70. 2011
  8. ncbi request reprint Generic low-molecular-weight heparins: some practical considerations
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA
    Semin Thromb Hemost 30:703-13. 2004
  9. pmc Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
    Jawed Fareed
    Departments of Pathology, Loyola University Medical Center, Maywood, Illinois, USA
    Thromb J 9:5. 2011
  10. ncbi request reprint Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile
    Jawed Fareed
    Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
    Curr Pharm Des 10:983-99. 2004

Detail Information

Publications125 found, 100 shown here

  1. ncbi request reprint Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques
    M Demir
    Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 7:38-43. 2001
    ..The sensitivity of ECT was adjusted by varying the concentration of the ecarin reagent. The results suggest that HCII-mediated inhibition of thrombin can be detected by using ECT reagents...
  2. ncbi request reprint Development of generic low molecular weight heparins: a perspective
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 19:53-68, v-vi. 2005
    ..Some objective guidelines for the proper development of these drugs are needed. Only expert groups and advisory panels to the regulatory bodies can develop these guidelines...
  3. ncbi request reprint Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    J Fareed
    Hemostasis and Thrombosis Research Laboratoires, Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 27:176-92. 2008
    ..Heparins, warfarin and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders for years to come...
  4. doi request reprint Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Jawed Fareed
    Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 14:385-92. 2008
    ..When these data are not available, the dosing and administration of low molecular weight heparins must be adapted from existing data and recommendations...
  5. doi request reprint Metabolic differences of current thienopyridine antiplatelet agents
    Jawed Fareed
    Loyola University Chicago, Department of Pathology and Pharmacology, 2160 S First Avenue, Maywood, Illinois 60153, USA
    Expert Opin Drug Metab Toxicol 9:307-17. 2013
    ..These drugs have distinct metabolic pathways, which lead to the formation of active metabolites that produce both observed clinical differences as well as pharmacokinetic and pharmacodynamic differences in response...
  6. ncbi request reprint Antithrombin and anti-Xa agents in the control of thrombogenesis
    J Fareed
    Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, IL, USA
    Pharmazie 56:S12-21. 2001
    ..Recent developments as well as future trends in the area of thrombin inhibitors and anti-Xa agents are reviewed...
  7. doi request reprint A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population
    Jawed Fareed
    Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 17:164-70. 2011
    ..9% (9 of 114) had antibovine antibodies and 3.5% (4 of 114) had human antithrombin antibodies, suggesting that antibodies may arise from contact with antigenic sources other than bovine-derived thrombin...
  8. ncbi request reprint Generic low-molecular-weight heparins: some practical considerations
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA
    Semin Thromb Hemost 30:703-13. 2004
    ..Thus, until the establishment of valid regulatory guidelines for the generic interchangeability of the commercially available LMWHs is completed, generic substitutes are not recommended...
  9. pmc Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
    Jawed Fareed
    Departments of Pathology, Loyola University Medical Center, Maywood, Illinois, USA
    Thromb J 9:5. 2011
    ..abstract:..
  10. ncbi request reprint Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile
    Jawed Fareed
    Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
    Curr Pharm Des 10:983-99. 2004
    ..Based on the available literature, it can be concluded that each product exhibits individuality...
  11. doi request reprint Old versus new oral anticoagulants: focus on pharmacology
    Jawed Fareed
    Departments of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Annu Rev Pharmacol Toxicol 52:79-99. 2012
    ..In this review, the pharmacology of warfarin and the pharmacology of the newly developed oral anti-Xa and antithrombin agents are discussed...
  12. doi request reprint Survival of heparins, oral anticoagulants, and aspirin after the year 2010
    Jawed Fareed
    Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois, USA
    Semin Thromb Hemost 34:58-73. 2008
    ..Heparins, warfarin, and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders beyond 2010...
  13. ncbi request reprint Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications
    D Fareed
    Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 10:357-64. 2004
    ..In addition, the observed hemodynamic changes in some of the cancer patients may be due to increased NO production...
  14. ncbi request reprint Small-molecule direct antithrombins: argatroban
    Jawed Fareed
    Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    Best Pract Res Clin Haematol 17:127-38. 2004
    ....
  15. ncbi request reprint Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis
    Jawed Fareed
    Departments of Pathology and Pharmacology, Hemostasis and Thrombosis Research Laboratories, Loyola University Chicago, Maywood, Illinois 60153, USA
    Semin Thromb Hemost 30:89-104. 2004
    ..These agents may not have the broad clinical spectrum as that observed with the heparins. More recently, several pharmaceutical companies have produced generic LMWHs...
  16. ncbi request reprint Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice
    Jawed Fareed
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA
    Clin Pharmacokinet 42:1043-57. 2003
    ..There are important pharmacokinetic and pharmacodynamic differences between enoxaparin, other LMWHs and UFH, and therefore these molecules cannot be regarded as interchangeable...
  17. ncbi request reprint Practical issues in the development of argatroban: a perspective
    Jawed Fareed
    Departments of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Pathophysiol Haemost Thromb 32:56-65. 2002
    ..The pharmacological profile of argatroban is unique as this antithrombin drug not only inhibits thrombogenesis but also modulates cellular functions. Because of its broad spectral actions, argatroban will have more expanded indications...
  18. ncbi request reprint Management of thrombotic and cardiovascular disorders in the new millenium
    Jawed Fareed
    Hemostasis and Thrombosis Research Unit, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 9:101-8. 2003
    ....
  19. doi request reprint Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide
    Cafer Adiguzel
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 15:501-11. 2009
    ..These results warrant further investigation of sulodexide in additional preclinical and clinical studies...
  20. doi request reprint Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin
    Angel Gray
    Department of Pharmacology, Loyola University Chicago, IL, USA
    Clin Appl Thromb Hemost 18:166-73. 2012
    ..The OSCSs significantly increased anti-Xa activity in ex vivo blood samples. These results indicate that various sources of OSCS affect the hemostatic properties of heparin...
  21. doi request reprint A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin
    Walter P Jeske
    Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, USA
    Thromb Res 128:361-7. 2011
    ..Semuloparin and bemiparin are two depolymerized heparins produced by distinct manufacturing processes. The objective of this investigation was to determine whether a common standard could be used to define their potency...
  22. doi request reprint Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin
    Cafer Adiguzel
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 15:145-51. 2009
    ..These observations suggest that the OSCS contaminant in the recalled heparin triggers an immunogenic response not seen with OSCS-contaminated free heparin...
  23. ncbi request reprint Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides
    Qing Ma
    Department of Pharmacology and Experimental Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
    Thromb Res 119:653-61. 2007
    ..Our findings indicated that TFPI release is dependent on the molecular weight of heparin and its derivatives. Heparin oligosaccharides exert their vascular effects through increased TFPI release after long-term repeated administration...
  24. ncbi request reprint Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan
    Jyothi Maddineni
    Loyola University Medical Center, Thrombosis and Hemostasis Research Laboratories, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 10:27-37. 2004
    ....
  25. ncbi request reprint Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants
    Mahmut Tobu
    Loyola University Medical Center, Department of Pathology, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 10:301-9. 2004
    ..These data also warrant the development clinically relevant methods for the monitoring of the concomitant use of newly developed anti-Xa and anti-IIa drugs with oral anticoagulants...
  26. doi request reprint Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates
    Debra A Hoppensteadt
    Department of Pathology, Loyola University Chicago, Chicago, Illinois, USA
    Clin Appl Thromb Hemost 16:13-20. 2010
    ..In conclusion, MPS showed a stronger release of TFPI than heparin that was not associated with a strong anticoagulant effect. Moreover, MPS downregulated TAFI, resulting in an enhanced fibrinolytic effect...
  27. ncbi request reprint Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis
    Sarfraz Ahmad
    Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, USA
    Mol Cell Biochem 258:163-70. 2004
    ....
  28. ncbi request reprint Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use
    Mahmut Tobu
    Department of Pathology and Pharmacology, Loyola University, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 9:1-17. 2003
    ..DX-9065a did not affect the ecarin clotting time and thrombin time at concentrations up to 12.5 microgram/mL. Because DX-9065a prolonged the dRVVT, this may impact diagnostic screening of patients with systemic lupus erythematosus...
  29. ncbi request reprint Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients
    Sarfraz Ahmad
    Loyola University of Chicago, Stritch School of Medicine, Maywood, Ill, USA
    Arch Pathol Lab Med 127:584-8. 2003
    ....
  30. ncbi request reprint Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate
    Jyothi Maddineni
    Department of Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 13:52-64. 2007
    ..These studies warrant further in vivo investigation to validate the relative neutralization profile of sulfaminoheparosans...
  31. ncbi request reprint Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor
    Mahmut Tobu
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 10:225-32. 2004
    ..These data provide the rationale for a novel mechanism of thrombosis through increased activity of CRP, nitric oxide, and TAFI, leading to fibrinolytic deficit and thrombosis in patients treated with erythropoietin...
  32. ncbi request reprint Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates
    Qing Ma
    Department of Pharmacology and Experimental Therapeutics, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
    Thromb Res 112:249-55. 2003
    ..These differences could be attributed to the endogenous release of tissue factor pathway inhibitor (TFPI) by C3 at higher doses, which is associated with the vascular effects of C3...
  33. ncbi request reprint Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications
    Jyothi Maddineni
    Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 12:267-76. 2006
    ....
  34. doi request reprint Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins
    Walter P Jeske
    Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois, USA
    Semin Thromb Hemost 34:74-85. 2008
    ..Until such guidelines are complete, generic interchange may not be feasible...
  35. ncbi request reprint Factor Xa inhibitors
    Jeanine M Walenga
    Department of Thoracic Cardiovascular Surgery, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL, USA
    Methods Mol Med 93:95-117. 2004
  36. doi request reprint In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative
    Jacqueline Kuziej
    Department of Pathology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 16:377-86. 2010
    ..These results suggest that PMX 60056 may provide an improved approach for the neutralization of UFH and LMWHs...
  37. doi request reprint Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications
    Eduardo Ramacciotti
    Department of Pathology and Pharmacology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 17:126-35. 2011
    ..The contaminant isolated from contaminated heparin was oversulfated chondroitin sulfate (OSCS). Other possible contaminants should be evaluated...
  38. doi request reprint Comparison of immunogenic potentials of bovine thrombin preparations
    He Zhu
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 15:41-9. 2009
    ..These results suggest that despite the presence of a trace amount of bovine factor Va antigen in bovine thrombin preparations, these contaminants failed to elicit the generation of antibodies against factor Va light chain in rabbit...
  39. ncbi request reprint Laboratory analysis of blood samples from patients treated with tinzaparin
    Debra A Hoppensteadt
    Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, Illinois, USA
    Semin Thromb Hemost 30:49-55. 2004
    ..TAT may be a useful test in monitoring the resolution of the clots. However, additional clinical validation is required to demonstrate the relevance of these parameters with the clinical outcome...
  40. doi request reprint Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin
    Justin W Griffin
    Loyola University Chicago Stritch School of Medicine, 2160 S First Ave, Maywood, IL, USA
    Clin Appl Thromb Hemost 17:567-71. 2011
    ..When comparing low-molecular-weight heparin (LMWH) with UFH, the incidence of new antiheparin-PF4 antibody production is higher in patients treated with UFH...
  41. doi request reprint Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine, human, and recombinant thrombin
    Nasir Sadeghi
    Department of Pathology and Pharmacology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 18:243-8. 2012
    ..Anti-JMI Abs did not cross-react with Recothrom, and Evithrom. Also, anti-Evithrom did not show any cross-reactivity with Recothrom and JMI at any time...
  42. ncbi request reprint Heparin oligosaccharides as potential therapeutic agents in senile dementia
    Qing Ma
    Department of Pharmacology and Experimental Therapeutics, Stritch School ofMedicine, Loyola University Chicago, Maywood, IL 60153, USA
    Curr Pharm Des 13:1607-16. 2007
    ..Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents...
  43. ncbi request reprint Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis
    Jyothi Maddineni
    Department of Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 12:311-7. 2006
    ..Thus the therapeutic effects of bioheparins in the TF-mediated pathogenesis of platelet activation may be similar to those of heparins...
  44. doi request reprint Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application
    He Zhu
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 15:32-40. 2009
    ....
  45. ncbi request reprint Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies
    Brian Untch
    Department of Pathology, Stritch School of Medicine, Loyola University of Chicago, Maywood, IL 60153, USA
    Thromb Res 106:149-56. 2002
    ..25 microg/ml. These data indicate that phylogenetic similarities in platelets of humans and primates may be used to further characterize the pathophysiology of HIT syndrome...
  46. doi request reprint Relative purity of different bovine thrombin preparations
    He Zhu
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 15:681-8. 2009
    ....
  47. doi request reprint Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom)
    - He Zhu
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 16:273-80. 2010
    ..Thus, the patients who were previously exposed to bovine thrombin may also develop antibodies which can cross-react with human recombinant thrombin...
  48. doi request reprint Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins
    Michael John Knesek
    Loyola Universtity Stritch School of Medicine Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 16:42-50. 2010
    ..9%) on day 7. C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha), and serum amyloid A were also increased after surgery. Tissue factor pathway inhibitor (TFPI) antigen levels were increased due to the treatment modalities...
  49. ncbi request reprint Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology
    Omer Iqbal
    Department of Pathology, Loyola University of Chicago, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 8:217-24. 2002
    ..The ECT system was found to be less sensitive when compared to other tests, and therefore, could be used as a point-of-care test during the PTCA/stenting procedures to monitor argatroban...
  50. doi request reprint Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation
    Debra Hoppensteadt
    Loyola University, Chicago, Illinois, USA
    Am J Cardiol 102:842-6. 2008
    ..Markers of inflammation were also decreased in the 2 groups...
  51. doi request reprint Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications
    Kelly Nelson
    Department of Pathology, Loyola University Chicago, IL 60153, USA
    Clin Appl Thromb Hemost 17:302-4. 2011
    ..Our study shows that ESRD patients exhibit activation of the coagulation and inflammatory processes...
  52. doi request reprint Pharmacology of argatroban
    Walter P Jeske
    Cardiovascular Institute, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Expert Rev Hematol 3:527-39. 2010
    ....
  53. ncbi request reprint Factor Xa inhibitors: today and beyond
    Jeanine M Walenga
    Departments of Pathology and Thoracic Cardiovascular Surgery, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Curr Opin Investig Drugs 4:272-81. 2003
    ..Thus, the inhibition of Factor Xa and its generation is an important strategy in the development of new antithrombotic drugs...
  54. ncbi request reprint Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies
    Sarfraz Ahmad
    Cardiovascular Institute, Loyola University Chicago, Maywood, IL, USA
    Thromb Res 108:49-55. 2002
    ..Clinical significance of the differential generation of HIT-associated antibodies remains unexplored at this time...
  55. doi request reprint Upregulation of inflammatory mediators in end-stage renal disease as measured using biochip array technology
    Rachael Davis
    Loyola University Medical Center, Maywood, IL, USA
    Clin Appl Thromb Hemost 17:E218-23. 2011
    ..This study further validates the role of endothelial damage and endogenous thrombotic processes in ESRD as evidenced by the increased levels of TM and DD...
  56. doi request reprint Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products
    Cafer Adiguzel
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 15:137-44. 2009
    ..The US FDA considers these drugs as follow-on agents whereas the EMEA classifies these drugs as biosimilar agents. Until clear guidelines are developed, generic interchange of LMWHs may not be feasible...
  57. ncbi request reprint In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice
    Rashid M Rashid
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Immunol Invest 36:183-201. 2007
    ..In conclusion, we found that HS did show immune-modulator properties in both normal and TB environments. Our studies reinforced the possibility that HS could one day be used as an immune-modulating therapeutic agent...
  58. doi request reprint Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels
    Walter P Jeske
    Cardiovascular Institute, Loyola University Chicago Medical Center, Maywood, Illinois 60153, USA
    Blood Coagul Fibrinolysis 22:206-10. 2011
    ..240 μg/kg). In summary, the AT level is a rate-limiting factor for the antithrombotic activity of fondaparinux...
  59. doi request reprint Comparative studies on branded enoxaparin and a US generic version of enoxaparin
    Jeanine M Walenga
    Department of Thoracic and Cardiovascular Surgery, Loyola University Chicago, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 19:261-7. 2013
    ..023). These findings suggest that simple analytical characterization can establish good quality control in manufacturing, but they may not assure similarity in biological performance between the branded and the generic enoxaparin...
  60. doi request reprint Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease
    Korosh Sharain
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 19:303-8. 2013
    ..Therefore, biomarkers may be able to evaluate the inflammatory state in kidney disease and potentially predict the cardiovascular risk...
  61. ncbi request reprint Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests
    Mahmut Tobu
    Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 8:325-36. 2002
    ..In the anti-Xa assay, modification of the incubation time was employed to extend the proper sensitivity range. These studies warrant further investigation to understand the mechanism of action of factor Xa inhibitors...
  62. doi request reprint Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens
    - He Zhu
    Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
    Clin Appl Thromb Hemost 16:522-8. 2010
    ....
  63. doi request reprint The future of anticoagulation
    Debra A Hoppensteadt
    Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA
    Semin Respir Crit Care Med 29:90-9. 2008
    ..It is conceivable that some of the newer drugs in combined modalities may mimic the broad therapeutic spectrum of heparins and warfarin. However, clinical validation is required for the therapeutic interchange for specific indications...
  64. ncbi request reprint The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3
    Qing Ma
    Department of Pharmacology and Experimental Therapeutics, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
    Thromb Res 105:447-53. 2002
    ..These findings were verified by intravenous administration of tritium-labeled C3 followed by detection of the radioactivity in the CSF and brain homogenates. These data suggest that ultralow MW HDO may pass through the BBB...
  65. ncbi request reprint Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation
    Debra Hoppensteadt
    Hemostasis and Thrombosis Research Laboratories, Department of Pathology and Pharmacology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA dhoppen lumc edu
    Hematol Oncol Clin North Am 17:313-41. 2003
    ..Ultra-LMWHs and synthetic heparinomimetics, such as fondaparinux, that exhibit a narrow pharmacologic spectrum will only be useful in specific indications and in combination with other drugs...
  66. doi request reprint A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates
    Walter Jeske
    Cardiovascular Institute, Department of Thoracic and CV Surgery, Loyola University Chicago, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 18:294-8. 2012
    ..In vivo behavior is an important consideration for defining pharmacoequivalence of complex biologic drugs...
  67. ncbi request reprint Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology
    Mark Walzer
    Department of Pharmacology, Loyola University Chicago Medical Center, 2160 South First Avenue, Rm 2638, Maywood, IL 60153, USA
    Eur J Pharmacol 445:211-20. 2002
    ....
  68. ncbi request reprint Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited
    Rolandas Gerbutavicius
    Loyola University Stritch School of Medicine, Maywood, IL, USA
    Clin Appl Thromb Hemost 8:115-24. 2002
    ..There was no significant difference between the reference intervals of subsets and the whole group (p > 0.05) calculated by both statistical techniques. Very few outliers were observed among these subjects in both tests...
  69. ncbi request reprint Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3
    Qing Ma
    Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
    Thromb Res 105:303-9. 2002
    ..In addition, the low anticoagulant effect of C3 suggests that this compound could be a relatively low-risk adjunct in the treatment of AD...
  70. ncbi request reprint Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG
    Brian Untch
    Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
    Thromb Res 105:117-23. 2002
    ..Together, these data indicate that IgG is the principal mediator of platelet activation in patients with HIT, with IgA and IgM playing a less significant role in the pathophysiology of this syndrome...
  71. doi request reprint Laboratory evaluation of the antiphospholipid syndrome
    Debra A Hoppensteadt
    Department of Pathology, Stritch School of Medicine, Loyola University Chicago, 2160 S First Avenue, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 22:19-32, v. 2008
    ..This article describes the laboratory diagnosis of APLS, including the detection of lupus anticoagulants, anticardiolipin antibodies, and subtypes of antiphospholipid antibodies...
  72. ncbi request reprint Heparin to pentasaccharide and beyond: the end is not in sight
    Harry L Messmore
    Loyola University Medical Center, Maywood, Illinois 60153, USA
    Semin Thromb Hemost 30:81-8. 2004
    ..Since then, this drug has been studied extensively to prove its clinical efficacy and safety...
  73. doi request reprint European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats
    Cafer Adiguzel
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 15:645-51. 2009
    ..On review of the preclinical and clinical data on the safety and efficacy, the European Union and U.S. Food and Drug Administration (US-FDA) have recently approved the use of rhAT in specified clinical indications...
  74. ncbi request reprint Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates
    Walter Jeske
    Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois, USA
    Semin Thromb Hemost 30:41-7. 2004
    ..For a proper pharmacodynamic analysis, multiple assays should be considered, given that both UFH and LMWHs are polycomponent in nature...
  75. pmc Coagulation profiling of random-source cats
    Elizabeth McGeehan
    Department of Comparative Medicine, Loyola University Medical Center, Maywood, Illinois, USA
    J Am Assoc Lab Anim Sci 49:27-30. 2010
    ..These studies suggest that the class B cats exhibited sufficiently wide variations in their coagulation parameters that they may not be optimal subjects for vascular or cardiovascular research...
  76. ncbi request reprint Differentiation of low-molecular-weight heparins: practical implications
    Jawed Fareed
    Thrombosis and Hemostasis Laboratories Loyola University Medical Center 2160 S First Avenue Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 10:299-300. 2004
  77. ncbi request reprint Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology
    Debra A Hoppensteadt
    Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, Illinois, USA
    Semin Thromb Hemost 30:105-8. 2004
  78. ncbi request reprint Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes
    J Fareed
    Loyola University Medical Center, Department of Pathology, Maywood, IL 60153, USA
    Clin Chem 44:1845-53. 1998
    ..Some of these tests may prove to be useful in clinical diagnosis and management of acute coronary syndromes. Clinical outcome studies are needed to determine which tests may be cost effective and medically useful...
  79. ncbi request reprint Air travel-associated venous thromboembolism
    Omer Iqbal
    Department of Pathology, Loyola University Medical Center, Maywood, Ill 60153, USA
    Med Princ Pract 12:73-80. 2003
    ....
  80. ncbi request reprint The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?
    Wasim Haque
    Thrombo Therapeutics Inc, 103 Advanced Technology Center, Edmonton, Alberta, CA, USA
    Compr Ther 32:261-6. 2006
    ..The advent of cyclooxygenase-2 inhibitors has been both a blessing and a curse for pain management. An in-depth understanding of the biological molecules in the arachidonic acid metabolism may alleviate pain without risk...
  81. ncbi request reprint Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
    Jeanine M Walenga
    Department of Pathology, Loyola University Medical Center, 2160 S First Avenue, Maywood, Illinois 60153, USA
    Expert Opin Investig Drugs 11:397-407. 2002
    ..At present, laboratory monitoring is not recommended. Clinical trials for treatment of established thrombosis, coronary syndromes and adjunct to thrombolytic therapy are in progress...
  82. ncbi request reprint Short- and long-acting synthetic pentasaccharides as antithrombotic agents
    Jeanine M Walenga
    Cardiovascular Institute 110 5226, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Expert Opin Investig Drugs 14:847-58. 2005
    ..Both drugs are being developed as antithrombotics for venous and arterial thrombosis, acute coronary syndrome, stroke and as adjuncts to thrombolytic therapy...
  83. ncbi request reprint Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates
    D A Hoppensteadt
    Department of Pathology, Loyola University Chicago, 2160 S gt First Avenue, Maywood, IL 60153, USA
    Thromb Res 103:157-63. 2001
    ..05). It is proposed that the ability of the topically administered MPS to increase the free and total TFPI levels may be one of the modes of action that contributes to the anticoagulant and anti-inflammatory actions of this agent...
  84. ncbi request reprint Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate
    M Clark
    Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 27:370-6. 2008
    ..As a result, oversulfated chondroitin sulfate was found to be the main determinant of the observed adverse reactions. This glycosaminoglycan is not usually found in the mammalian tissues...
  85. ncbi request reprint Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications
    M Florian-Kujawski
    Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 23:346-54. 2004
    ..Low molecular weight heparins (LMWHs) have different antithrombin/anti-Xa profiles and therefore vary in the degree to which they inhibit TAFI. The purpose of this study was to determine the differential regulation of TAFI by LMWHs...
  86. ncbi request reprint Influence of different anticoagulant agents on fibrinopeptide a generation
    M Tobu
    Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 9:273-92. 2003
    ..A strong correlation between Hemochron ACT and FPA generation inhibition was observed. Based on this significant correlation, the FPA generation inhibition can be predicted by point-of-care ACT assay...
  87. ncbi request reprint Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I
    M Demir
    Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 7:44-52. 2001
    ..These results suggest that SH is a strong anticoagulant with comparable properties to mammalian heparins and can be used in the development of clinically useful antithrombotic-anticoagulant drugs...
  88. ncbi request reprint Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    B E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Circulation 103:1838-43. 2001
    ..We report a prospective, historical- controlled study evaluating the efficacy and safety of argatroban, a direct thrombin inhibitor, as anticoagulant therapy in patients with HIT or HIT with thrombosis syndrome (HITTS)...
  89. ncbi request reprint Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats
    Thyyar M Ravindranath
    Ronald McDonald Children s Hospital, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 10:379-85. 2004
    ..These results suggest that burn, septic, and their combined injuries perturb coagulation cascade and thrombotic process toward the procoagulant pathway by impairing fibrinolysis...
  90. ncbi request reprint Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization
    O Iqbal
    Department of Pathology, Loyola University Medical Center, 2160 S First Ave, Building 102, Room 2646, Maywood, IL 60153, USA
    J Card Surg 20:42-51. 2005
    ..The calculated circulating concentrations of Refludan, following a bolus administration, based on the ECT cards, liquid ECT and APTT were 3.20 +/- 1.3, 3.51 +/- 1.35 and 2.02 +/- 1.19 microg/mL, respectively...
  91. ncbi request reprint Comparative tissue factor pathway inhibitor release potential of heparins
    M Tobu
    Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 11:37-47. 2005
    ..The influence of molecular weight, charge density, and interactions with heparin cofactor II on TFPI release are also discussed...
  92. ncbi request reprint Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis
    M Florian-Kujawski
    Loyola University Medical Center, Maywood, IL, USA
    Int Angiol 23:246-54. 2004
    ..The purpose of this study was to identify unique proteomic biomarkers present in patients with ACS using a newly developed proteomic profiling technique, surface enhanced laser desorption/ionization (SELDI)...
  93. ncbi request reprint A survey of venous thrombosis models
    Walter P Jeske
    Department of Thoracic Cardiovascular Surgery, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL, USA
    Methods Mol Med 93:221-37. 2004
  94. ncbi request reprint Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review
    H L Messmore
    Department of Medicine, Loyola University Medical Center, IL, USA
    Curr Pharm Des 10:1001-10. 2004
    ..A new synthetic version of (pentasaccharide) both heparin and LMWH has been at least if not more effective than one LMWH (enoxaparin)...
  95. ncbi request reprint Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies
    S Ahmad
    Cardiovascular Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA
    Clin Appl Thromb Hemost 5:259-66. 1999
    ....
  96. ncbi request reprint Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88)
    M Demir
    Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 7:131-40. 2001
    ..Because of the molecular characteristics and the dual nature of the pharmacologic action of PI-88, this agent represents an attractive pharmacologic agent for the control of thrombotic and proliferative disorders...
  97. ncbi request reprint Isoamyl nitrite depolymerized heparin as a universal calibrator for heparins and low molecular weight heparins
    A Ahsan
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 6:169-74. 2000
    ..Besides, ultraviolet detection is not needed for molecular weight calculations. Therefore, it is proposed that its feasibility as a universal reference calibrator for both heparins and low molecular weight heparins be considered...
  98. ncbi request reprint Low molecular weight heparins: are they different?
    J Fareed
    Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois, USA
    Can J Cardiol 14:28E-34E. 1998
    ..The effect of repeated administration of LMWH mimicking the postsurgical prophylaxis of DVT exhibited product-based augmentation of the antithrombotic or hemorrhagic effects...
  99. ncbi request reprint Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease
    D H Van Thiel
    Department of Medicine, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA
    Thromb Haemost 85:667-70. 2001
    ..TAFI levels were very low and essentially undetectable in the plasma of patients with advanced hepatocellular liver disease. No relationship with the degradation products of fibrin was evident...
  100. ncbi request reprint Hemostatic modulation with the liver dialysis device in humans with advanced liver disease
    Magdalene M George
    Department of Medicine Hepatology Gastroenterology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA
    Hepatogastroenterology 49:1333-9. 2002
    ..To determine the alterations in coagulation and fibrinolysis occurring in patients treated with the liver dialysis device...
  101. ncbi request reprint Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist
    S Ahmad
    Department of Thoracic and Cardiovascular Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
    Thromb Res 102:143-51. 2001
    ..This suggests that the simultaneous administration of GPIIb/IIIa receptor antagonist with LMWH may not have any added benefit in the clinical management of patients with ACS...